Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
doi:10.1002/cncr.21589
Archived from the original on 26 April 2015
More than a decade later, in 2005, exenatide (a synthetic version of exendin-4) was approved as the first anti-diabetes medication in the GLP-1 receptor agonist class by the U.S
: Antibody-Drug Conjugate (ADC) CDMO Services Peptide-Drug Conjugate CDMO Services Oligonucleotide Conjugate CDMO Services Protein Conjugate CDMO Services Others : Pharmaceutical Companies Biotechnology Companies Research Institutes Others : North America Europe Asia-Pacific South America Middle East & Africa : Lonza Catalent Samsung Biologics WuXi AppTec AGC Biologics Axplora Sterling Pharma Solutions BSP Pharmaceuticals S.p.A
Diabetic retinopathy or active retinal disease
US$ 24.16
US$ 27.59
US$ 25.43
